JP7074758B2 - ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン - Google Patents
ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン Download PDFInfo
- Publication number
- JP7074758B2 JP7074758B2 JP2019534197A JP2019534197A JP7074758B2 JP 7074758 B2 JP7074758 B2 JP 7074758B2 JP 2019534197 A JP2019534197 A JP 2019534197A JP 2019534197 A JP2019534197 A JP 2019534197A JP 7074758 B2 JP7074758 B2 JP 7074758B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- isopropyl
- amine
- pyridyl
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600784 | 2016-12-22 | ||
| DKPA201600784 | 2016-12-22 | ||
| DKPA201700404 | 2017-07-06 | ||
| DKPA201700404 | 2017-07-06 | ||
| PCT/EP2017/083721 WO2018115067A1 (en) | 2016-12-22 | 2017-12-20 | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502230A JP2020502230A (ja) | 2020-01-23 |
| JP2020502230A5 JP2020502230A5 (https=) | 2021-01-28 |
| JP7074758B2 true JP7074758B2 (ja) | 2022-05-24 |
Family
ID=60812077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534197A Expired - Fee Related JP7074758B2 (ja) | 2016-12-22 | 2017-12-20 | ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10351561B2 (https=) |
| EP (1) | EP3558988B1 (https=) |
| JP (1) | JP7074758B2 (https=) |
| KR (1) | KR20190095301A (https=) |
| CN (1) | CN110099901B (https=) |
| AU (1) | AU2017384481A1 (https=) |
| BR (1) | BR112018017067A2 (https=) |
| CA (1) | CA3046588A1 (https=) |
| CL (1) | CL2019001669A1 (https=) |
| CO (1) | CO2019005538A2 (https=) |
| CR (1) | CR20190302A (https=) |
| DO (1) | DOP2019000169A (https=) |
| EC (1) | ECSP19043790A (https=) |
| ES (1) | ES2882335T3 (https=) |
| IL (1) | IL267561A (https=) |
| JO (1) | JOP20190126A1 (https=) |
| MX (1) | MX2019007509A (https=) |
| PE (1) | PE20191323A1 (https=) |
| PH (1) | PH12019501324A1 (https=) |
| RU (1) | RU2019116251A (https=) |
| TW (1) | TW201829405A (https=) |
| WO (1) | WO2018115067A1 (https=) |
| ZA (1) | ZA201904236B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| EP3723807B1 (en) | 2017-12-14 | 2021-10-20 | H. Lundbeck A/S | Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| WO2019121840A1 (en) | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
| US20230121698A1 (en) * | 2019-12-23 | 2023-04-20 | Sanford Burnham Prebys Medical Discovery Institute | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002524512A (ja) | 1998-09-16 | 2002-08-06 | ブリストル−マイヤーズ スクイブ カンパニー | ｃＧＭＰホスホジエステラーゼの縮合ピリジン阻害剤 |
| JP2008505056A (ja) | 2004-07-05 | 2008-02-21 | アステラス製薬株式会社 | ピラゾロピリジン誘導体 |
| JP2012510996A (ja) | 2008-12-06 | 2012-05-17 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP2016516791A (ja) | 2013-04-18 | 2016-06-09 | ハー・ルンドベック・アクチエゼルスカベット | Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物 |
| WO2016170064A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as pde1 inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7652035B2 (en) | 2004-10-19 | 2010-01-26 | Neurocrine Bioscience, Inc. | CRF receptor antagonists and methods relating thereto |
| WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
| NZ579645A (en) | 2007-03-14 | 2012-01-12 | Ranbaxy Lab Ltd | Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors |
| WO2009067607A2 (en) * | 2007-11-20 | 2009-05-28 | Memory Pharmaceuticals Corporation | Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders |
| EP2828253A1 (en) | 2012-03-19 | 2015-01-28 | Abide Therapeutics, Inc. | Carbamate compounds and of making and using same |
| WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
| US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| TW201639851A (zh) | 2015-03-16 | 2016-11-16 | 大日本住友製藥股份有限公司 | 雙環咪唑衍生物 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
-
2017
- 2017-06-16 JO JOP/2019/0126A patent/JOP20190126A1/ar unknown
- 2017-12-19 TW TW106144606A patent/TW201829405A/zh unknown
- 2017-12-20 WO PCT/EP2017/083721 patent/WO2018115067A1/en not_active Ceased
- 2017-12-20 BR BR112018017067A patent/BR112018017067A2/pt not_active Application Discontinuation
- 2017-12-20 ES ES17821622T patent/ES2882335T3/es active Active
- 2017-12-20 CN CN201780079553.2A patent/CN110099901B/zh not_active Expired - Fee Related
- 2017-12-20 CR CR20190302A patent/CR20190302A/es unknown
- 2017-12-20 RU RU2019116251A patent/RU2019116251A/ru not_active Application Discontinuation
- 2017-12-20 AU AU2017384481A patent/AU2017384481A1/en not_active Abandoned
- 2017-12-20 EP EP17821622.2A patent/EP3558988B1/en active Active
- 2017-12-20 KR KR1020197017840A patent/KR20190095301A/ko not_active Ceased
- 2017-12-20 PE PE2019001294A patent/PE20191323A1/es unknown
- 2017-12-20 CA CA3046588A patent/CA3046588A1/en not_active Abandoned
- 2017-12-20 JP JP2019534197A patent/JP7074758B2/ja not_active Expired - Fee Related
- 2017-12-20 MX MX2019007509A patent/MX2019007509A/es unknown
- 2017-12-21 US US15/849,798 patent/US10351561B2/en active Active
-
2019
- 2019-05-28 CO CONC2019/0005538A patent/CO2019005538A2/es unknown
- 2019-05-29 US US16/424,585 patent/US10689379B2/en active Active
- 2019-06-11 PH PH12019501324A patent/PH12019501324A1/en unknown
- 2019-06-17 CL CL2019001669A patent/CL2019001669A1/es unknown
- 2019-06-18 DO DO2019000169A patent/DOP2019000169A/es unknown
- 2019-06-19 EC ECSENADI201943790A patent/ECSP19043790A/es unknown
- 2019-06-20 IL IL267561A patent/IL267561A/en unknown
- 2019-06-27 ZA ZA2019/04236A patent/ZA201904236B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002524512A (ja) | 1998-09-16 | 2002-08-06 | ブリストル−マイヤーズ スクイブ カンパニー | ｃＧＭＰホスホジエステラーゼの縮合ピリジン阻害剤 |
| JP2008505056A (ja) | 2004-07-05 | 2008-02-21 | アステラス製薬株式会社 | ピラゾロピリジン誘導体 |
| JP2012510996A (ja) | 2008-12-06 | 2012-05-17 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP2016516791A (ja) | 2013-04-18 | 2016-06-09 | ハー・ルンドベック・アクチエゼルスカベット | Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物 |
| WO2016170064A1 (en) | 2015-04-22 | 2016-10-27 | H. Lundbeck A/S | Imidazotriazinones as pde1 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190095301A (ko) | 2019-08-14 |
| ECSP19043790A (es) | 2019-06-30 |
| BR112018017067A2 (pt) | 2019-07-02 |
| JP2020502230A (ja) | 2020-01-23 |
| EP3558988A1 (en) | 2019-10-30 |
| RU2019116251A (ru) | 2021-01-22 |
| CL2019001669A1 (es) | 2019-09-06 |
| MX2019007509A (es) | 2019-09-04 |
| RU2019116251A3 (https=) | 2021-03-31 |
| US20180179200A1 (en) | 2018-06-28 |
| WO2018115067A1 (en) | 2018-06-28 |
| ES2882335T3 (es) | 2021-12-01 |
| DOP2019000169A (es) | 2019-07-31 |
| US10689379B2 (en) | 2020-06-23 |
| TW201829405A (zh) | 2018-08-16 |
| ZA201904236B (en) | 2020-12-23 |
| CN110099901B (zh) | 2023-01-03 |
| JOP20190126A1 (ar) | 2019-05-28 |
| PH12019501324A1 (en) | 2019-09-16 |
| US20190352302A1 (en) | 2019-11-21 |
| US10351561B2 (en) | 2019-07-16 |
| EP3558988B1 (en) | 2021-07-07 |
| IL267561A (en) | 2019-08-29 |
| CR20190302A (es) | 2019-08-21 |
| PE20191323A1 (es) | 2019-09-24 |
| CN110099901A (zh) | 2019-08-06 |
| CO2019005538A2 (es) | 2019-06-11 |
| CA3046588A1 (en) | 2018-06-28 |
| AU2017384481A1 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7074758B2 (ja) | ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン | |
| CN114341127B (zh) | 作为hpk1抑制剂的氨基吡嗪化合物及其用途 | |
| JP7096171B2 (ja) | ＰＤＥ１阻害剤としての１Ｈ－ピラゾロ［４，３－ｂ］ピリジン | |
| KR102924294B1 (ko) | 아졸-융합된 피리다진-3(2h)-온 유도체 | |
| US12109198B2 (en) | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | |
| CA3067765A1 (en) | Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor | |
| JP7112413B2 (ja) | Ｐｄｅ１阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン | |
| CA2933480A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| TW202404952A (zh) | Qpctl及qpct之抑制劑 | |
| JP2021508685A (ja) | ＰＤＥ１阻害剤としての１Ｈ−ピラゾロ［４，３−ｂ］ピリジン | |
| JP2021506868A (ja) | Ｐｄｅ１阻害剤としての大環状分子 | |
| JP2021506775A (ja) | １ｈ−ピラゾロ［４，３−ｂ］ピリジンの投与を含む併用治療 | |
| JP2021506780A (ja) | １ｈ−ピラゾロ［４，３−ｂ］ピリジンの投与を含む併用治療 | |
| JP2021506876A (ja) | ＰＤＥ１阻害剤としてのピラゾロ［３，４−ｂ］ピリジン及びイミダゾ［１，５−ｂ］ピリダジン | |
| TW202509019A (zh) | Sarm1調節子、其製劑及用途 | |
| JP6977038B2 (ja) | Ｇｓｋ−３阻害剤 | |
| HK40011732B (en) | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors | |
| HK40011732A (en) | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors | |
| KR20260005343A (ko) | Mrgprx2 억제제 및 이의 사용 방법 | |
| TW202602873A (zh) | 新穎降解劑化合物及其用途 | |
| US20260125346A1 (en) | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | |
| EA053259B1 (ru) | Конденсированные с азолом производные пиридазин-3(2н)-она | |
| TW202610642A (zh) | Pde3a/slfn12干擾物、製備及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201207 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211028 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220419 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220512 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7074758 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |